Patents by Inventor Joseph Vacca

Joseph Vacca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY
    Publication number: 20240132506
    Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):
    Type: Application
    Filed: November 3, 2023
    Publication date: April 25, 2024
    Applicant: Kronos Bio, Inc.
    Inventors: Peter MIKOCHIK, Joseph VACCA, David FREEMAN, Andrew S. TASKER
  • Modulators of HSD17B13 and methods of use thereof
    Patent number: 11957687
    Abstract: The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: April 16, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11932636
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
    Patent number: 11845754
    Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: December 19, 2023
    Assignee: Kronos Bio, Inc.
    Inventors: Peter Mikochik, Joseph Vacca, David Freeman, Andrew S. Tasker
  • MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF
    Publication number: 20230094341
    Abstract: The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
    Type: Application
    Filed: July 1, 2020
    Publication date: March 30, 2023
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: Joseph VACCA
  • Combinations of RAD51 and PARP inhibitors
    Patent number: 11607404
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • INHIBITORS OF ENL/AF9 YEATS
    Publication number: 20230027198
    Abstract: Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.
    Type: Application
    Filed: December 17, 2020
    Publication date: January 26, 2023
    Inventors: Tanweer A. KHAN, Nigel LIVERTON, Yoshiyuki FUKASE, Mayako MICHINO, Andrew W. STAMFORD, Michael W. MILLER, David HUGGINS, Peter MEINKE, David C. ALLIS, Liling WAN, Tammy LADDUWAHETTY, Joseph VACCA
  • RAD51 INHIBITORS
    Publication number: 20220259198
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: December 16, 2021
    Publication date: August 18, 2022
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • Inhibitors of lysine gingipain
    Patent number: 11332464
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: May 17, 2022
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11291655
    Abstract: This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 5, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca
  • RAD51 INHIBITORS
    Publication number: 20220056022
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 24, 2022
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • RAD51 inhibitors
    Patent number: 11247988
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: February 15, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY
    Publication number: 20220002305
    Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Applicant: Kronos Bio, Inc.
    Inventors: Peter MIKOCHIK, Joseph VACCA, David FREEMAN, Andrew S. TASKER
  • Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
    Patent number: 11155560
    Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 26, 2021
    Assignee: kronos bio, inc.
    Inventors: Peter Mikochik, Joseph Vacca, David Freeman, Andrew S. Tasker
  • RAD51 inhibitors
    Patent number: 11084812
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Pyrazole compounds and uses thereof
    Patent number: 11072599
    Abstract: The present invention provides pyrazole derivatives of Formula (I), and in particular N1-(4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl) pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as casein kinase 1 (CK1) and/or interleukin 1 receptor associated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: July 27, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Dansu Li, Irit Snir-Alkalay, Joseph Vacca, Yinon Ben-Neriah, Avanthika Venkatachalam
  • Bis-benzimidazole compounds and methods of using the same
    Patent number: 10961202
    Abstract: Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: March 30, 2021
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, EXPANSION THERAPEUTICS, INC.
    Inventors: Matthew Disney, Timothy Allen Blizzard, Suzanne Rzuczek, John Ndungu, Joseph Vacca, Andy Jennings, Alexei Pushechnikov
  • Pyrazole pyrimidine derivative and uses thereof
    Patent number: 10960003
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: March 30, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
  • Inhibitors of arginine gingipain
    Patent number: 10906881
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 2, 2021
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
  • INHIBITORS OF LYSINE GINGIPAIN
    Publication number: 20210017167
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 4, 2020
    Publication date: January 21, 2021
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca